Page 397 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 397
INVENTIVA 250 C
Rue de Dijon, 50
Daix, 21121
France
www.inventivapharma.com
Inventiva is a drug discovery company that focuses on therapeutic approaches involving
transcription factors and epigenetic targets (particularly the HKMT family) to discover
innovative treatments for cancer and fibrosis.The company’s business strategy is to engage in
proprietary research programs and secure drug discovery partnerships with pharmaceutical
groups. It also offers a full range of research services.These draw on its extensive technology
platform, a proprietary library of 240,000 compounds and a fibrosis platform. Inventiva also
has expertise in nuclear receptors, transcription factors and epigenetic modulation.
Janssen Pharmaceutical Companies of Johnson & Johnson 270
30, Turnhoutseweg
Beerse , B-2340
Belgium
www.janssen-emea.com
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing
and solving the most important unmet medical needs of our time, including oncology,
immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.
Driven by our commitment to patients, Janssen develops innovative products, services and
healthcare solutions to help people throughout the world. Janssen believes to effectively
fight hepatitis C, a serious commitment is required from all stakeholders to improve
the healthcare infrastructure across the continuum of care, increase awareness, provide
education and ensure access to effective treatment for people living with hepatitis C. Janssen
is working around the world to be a positive catalyst in the fight towards eradication of this
deadly disease and serious public health problem.
MEDA 430 A INDUSTRY INFORMATION
2A, Pipers väg
Solna, 17009
Sweden
www.meda.se
Meda is a leading international specialty pharma company, with own operations in over
60 countries and the products are sold in more than 150 countries. Meda has a well-
diversified product portfolio represented within several therapy areas including hepatology/
gastroenterology, with products such as Legalon and Legalon-SIL, silymarin and silibinin,
anti-toxic treatments for liver pathologies ranging from NASH to acute mushroom
poisoning. In particular, Silibinin has been granted the orphan drug designation from EMA
and FDA for the prevention of recurrent hepatitis C in liver transplant recipients and new
studies are ongoing. Find out more, visit www.meda.se.
Vienna, Austria • April 22–26, 2015 397
Rue de Dijon, 50
Daix, 21121
France
www.inventivapharma.com
Inventiva is a drug discovery company that focuses on therapeutic approaches involving
transcription factors and epigenetic targets (particularly the HKMT family) to discover
innovative treatments for cancer and fibrosis.The company’s business strategy is to engage in
proprietary research programs and secure drug discovery partnerships with pharmaceutical
groups. It also offers a full range of research services.These draw on its extensive technology
platform, a proprietary library of 240,000 compounds and a fibrosis platform. Inventiva also
has expertise in nuclear receptors, transcription factors and epigenetic modulation.
Janssen Pharmaceutical Companies of Johnson & Johnson 270
30, Turnhoutseweg
Beerse , B-2340
Belgium
www.janssen-emea.com
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing
and solving the most important unmet medical needs of our time, including oncology,
immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases.
Driven by our commitment to patients, Janssen develops innovative products, services and
healthcare solutions to help people throughout the world. Janssen believes to effectively
fight hepatitis C, a serious commitment is required from all stakeholders to improve
the healthcare infrastructure across the continuum of care, increase awareness, provide
education and ensure access to effective treatment for people living with hepatitis C. Janssen
is working around the world to be a positive catalyst in the fight towards eradication of this
deadly disease and serious public health problem.
MEDA 430 A INDUSTRY INFORMATION
2A, Pipers väg
Solna, 17009
Sweden
www.meda.se
Meda is a leading international specialty pharma company, with own operations in over
60 countries and the products are sold in more than 150 countries. Meda has a well-
diversified product portfolio represented within several therapy areas including hepatology/
gastroenterology, with products such as Legalon and Legalon-SIL, silymarin and silibinin,
anti-toxic treatments for liver pathologies ranging from NASH to acute mushroom
poisoning. In particular, Silibinin has been granted the orphan drug designation from EMA
and FDA for the prevention of recurrent hepatitis C in liver transplant recipients and new
studies are ongoing. Find out more, visit www.meda.se.
Vienna, Austria • April 22–26, 2015 397
